Marinus Pharmaceuticals, Inc. - Special Call Transcript
Ladies and gentlemen, thank you for standing by. Welcome to the Marinus Pharmaceuticals conference call to discuss the results of the company's Phase III CDKL5 deficiency disorder trial. My name is Chantal, and I will be your operator for today's call. (Operator Instructions) Please be advised that this call is being recorded at Marinus' request.
Now I would like to introduce our host for today's call, Sasha Damouni Ellis, Vice President, Investor Relations and Corporate Communications. Please go ahead.
Thank you, operator, and thank you all joining us today to discuss the results of our Phase III Marigold Study. With me from Marinus are Dr. Scott Braunstein, Chief Executive Officer; Dr. Joe Hulihan, Chief Medical Officer; and Edward Smith, Chief Financial Officer.
Before we begin, I would like to remind everyone that some of the statements made today could be deemed forward-looking under the securities laws. These forward-looking statements are
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |